Comparative Pharmacology
Head-to-head clinical analysis: LEXXEL versus PLENDIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEXXEL versus PLENDIL.
LEXXEL vs PLENDIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LEXXEL is a combination of felodipine, a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle and cardiac muscle, causing vasodilation and reduced myocardial contractility, and enalapril, an angiotensin-converting enzyme (ACE) inhibitor that prevents conversion of angiotensin I to angiotensin II, reducing vasoconstriction, aldosterone secretion, and sodium reabsorption.
Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
1 tablet (felodipine 5 mg / enalapril 5 mg) orally once daily, may increase to 2 tablets once daily after 2-4 weeks if needed.
Initial: 5 mg orally once daily. Maintenance: 2.5–10 mg orally once daily. Maximum: 10 mg/day.
None Documented
None Documented
Enalapril: ~1.3 hours; Enalaprilat: terminal half-life ~35-38 hours, with multiple-dose accumulation half-life ~11 hours; effective half-life for ACE inhibition ~24 hours.
Terminal elimination half-life 2-5 hours in healthy adults; 7-12 hours in patients with hepatic impairment or advanced age
Renal: ~35-50% as unchanged drug (enalaprilat), biliary/fecal: ~15-30% as metabolites and unchanged drug; total renal elimination of enalaprilat accounts for ~60-80% of dose.
Renal (approximately 70% as metabolites, <0.5% unchanged); fecal (approximately 10%)
Category C
Category C
ACE Inhibitor + Calcium Channel Blocker
Calcium Channel Blocker